Identification of a cyclin B1-derived CTL epitope eliciting spontaneous responses in both cancer patients and healthy donors

Cancer Immunology, Immunotherapy

Volumn 60, Issue 2, 2011, Pages 227-234

  Andersen, Rikke Sick ^a   Sørensen, Rikke Bæk ^a   Ritter, Cathrin ^b   Svane, Inge Marie ^a   Becker, Jürgen C ^b   Thor Straten, Per ^a   Andersen, Mads Hald ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF GRAZ   (Austria)

Author keywords

Anti cancer vaccination; CTL epitope; Cyclin B1; Cytotoxic T cells; Tumor associated antigen

Indexed keywords

CYCLIN B1; EPITOPE; GAMMA INTERFERON; HLA A2 ANTIGEN; ISOLEUCYLLEUCYLISOLEUCYLASPARTYLTRYPTOPHYLLEUCYLVALYLGLUTAMINYLVALINE; PEPTIDE; UNCLASSIFIED DRUG;

ADULT; AGED; AMINO ACID SEQUENCE; ARTICLE; BINDING AFFINITY; BREAST CANCER; CANCER CELL CULTURE; CELL CLONE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNOREACTIVITY; KIDNEY CARCINOMA; MALE; MELANOMA; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN LOCALIZATION; TUMOR IMMUNITY;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; ANTIBODIES; CELLS, CULTURED; CYCLIN B1; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES, T-LYMPHOCYTE; HEALTH; HLA-A2 ANTIGEN; HUMANS; MIDDLE AGED; NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 79151483123     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-010-0933-y     Document Type: Article

References (30)

1. L Novellino C Castelli G Parmiani 2005 A listing of human tumor antigens recognized by T cells: March 2004 update Cancer Immunol Immunother 54 187 207 1:CAS:528:DC%2BD2MXjs1ahug%3D%3D 10.1007/s00262-004-0560-6 15309328
2. FO Nestle S Alijagic M Gilliet Y Sun S Grabbe R Dummer G Burg D Schadendorf 1998 Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells Nat Med 4 328 332 1:CAS:528:DyaK1cXhs1Kisrc%3D 10.1038/nm0398-328 9500607
3. SA Rosenberg JC Yang DJ Schwartzentruber P Hwu FM Marincola SL Topalian NP Restifo ME Dudley SL Schwarz PJ Spiess JR Wunderlich MR Parkhurst Y Kawakami CA Seipp JH Einhorn DE White 1998 Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma Nat Med 4 321 327 1:CAS:528:DyaK1cXhs1Kju7c%3D 10.1038/nm0398-321 9500606
4. M Wobser P Keikavoussi V Kunzmann M Weininger MH Andersen JC Becker 2006 Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin Cancer Immunol Immunother 55 1294 1298 1:CAS:528:DC%2BD28Xmtl2qtbY%3D 10.1007/s00262-005-0102-x 16315030
5. A Riker J Cormier M Panelli U Kammula E Wang A Abati P Fetsch KH Lee S Steinberg S Rosenberg F Marincola 1999 Immune selection after antigen-specific immunotherapy of melanoma Surgery 126 112 120 1:STN:280:DyaK1MzosVyitg%3D%3D 10455872
6. MH Andersen IM Svane JC Becker P thor Straten 2007 The universal character of the tumor-associated antigen survivin Clin Cancer Res 13 5991 5994 1:CAS:528:DC%2BD2sXhtFygs7vN 10.1158/1078-0432.CCR-07-0686 17947459
7. RH Vonderheide 2008 Prospects and challenges of building a cancer vaccine targeting telomerase Biochimie 90 173 180 1:CAS:528:DC%2BD2sXhsVSqu7vM 10.1016/j.biochi.2007.07.005 17716803
8. M Yu Q Zhan OJ Finn 2002 Immune recognition of cyclin B1 as a tumor antigen is a result of its overexpression in human tumors that is caused by non-functional p53 Mol Immunol 38 981 987 1:CAS:528:DC%2BD38XjsFCltLc%3D 10.1016/S0161-5890(02)00026-3 12009577
9. AM Egloff LA Vella OJ Finn 2006 Cyclin B1 and other cyclins as tumor antigens in immunosurveillance and immunotherapy of cancer Cancer Res 66 6 9 1:CAS:528:DC%2BD28XhsFWrsA%3D%3D 10.1158/0008-5472.CAN-05-3389 16397206
10. H Kawamoto H Koizumi T Uchikoshi 1997 Expression of the G2-M checkpoint regulators cyclin B1 and cdc2 in nonmalignant and malignant human breast lesions: immunocytochemical and quantitative image analyses Am J Pathol 150 15 23 1:STN:280:DyaK2s7lvV2ktA%3D%3D 9006317
11. TA Tran JS Ross JA Carlson MC Mihm Jr 1998 Mitotic cyclins and cyclin-dependent kinases in melanocytic lesions Hum Pathol 29 1085 1090 1:CAS:528:DyaK1cXntFGgsbs%3D 10.1016/S0046-8177(98)90418-X 9781646
12. SO Ikuerowo MA Kuczyk M Mengel HE van der OB Shittu B Vaske U Jonas S Machtens J Serth 2006 Alteration of subcellular and cellular expression patterns of cyclin B1 in renal cell carcinoma is significantly related to clinical progression and survival of patients Int J Cancer 119 867 874 1:CAS:528:DC%2BD28XntVeqt7c%3D 10.1002/ijc.21869 16557593
13. E Ersvaer JY Zhang E McCormack A Olsnes N Anensen EM Tan BT Gjertsen O Bruserud 2007 Cyclin B1 is commonly expressed in the cytoplasm of primary human acute myelogenous leukemia cells and serves as a leukemia-associated antigen associated with autoantibody response in a subset of patients Eur J Haematol 79 210 225 1:CAS:528:DC%2BD2sXhtV2rtrbN 10.1111/j.1600-0609.2007.00899.x 17655707
14. H Kao JA Marto TK Hoffmann J Shabanowitz SD Finkelstein TL Whiteside DF Hunt OJ Finn 2001 Identification of cyclin B1 as a shared human epithelial tumor-associated antigen recognized by T cells J Exp Med 194 1313 1323 1:CAS:528:DC%2BD3MXot12msbY%3D 10.1084/jem.194.9.1313 11696596
15. HG Rammensee J Bachmann NPN Emmerich OA Bachor S Stevanovic 1999 SYFPEITHI: database for MHC ligands and peptide motifs Immunogenetics 50 213 219 1:CAS:528:DyaK1MXntlalsbs%3D 10.1007/s002510050595 10602881
16. S Buus SL Lauemoller P Worning C Kesmir T Frimurer S Corbet A Fomsgaard J Hilden A Holm S Brunak 2003 Sensitive quantitative predictions of peptide-MHC binding by a 'Query by Committee' artificial neural network approach Tissue Antigens 62 378 384 1:CAS:528:DC%2BD3sXpsVOiur0%3D 10.1034/j.1399-0039.2003. 00112.x 14617044
17. M Nielsen C Lundegaard P Worning SL Lauemoller K Lamberth S Buus S Brunak O Lund 2003 Reliable prediction of T-cell epitopes using neural networks with novel sequence representations Protein Sci 12 1007 1017 1:CAS:528: DC%2BD3sXjtl2jtL8%3D 10.1110/ps.0239403 12717023
18. KC Parker MA Bednarek JE Coligan 1994 Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains J Immunol 152 163 175 1:CAS:528:DyaK2cXhtlWlsLY%3D 8254189
19. J Elvin C Potter T Elliott V Cerundolo A Townsend 1993 A method to quantify binding of unlabeled peptides to class I MHC molecules and detect their allele specificity J Immunol Methods 158 161 171 1:CAS:528:DyaK3sXkvFeitrc%3D 10.1016/0022-1759(93)90210-X 7679131
20. MH Andersen L Tan I Sondergaard J Zeuthen T Elliott JS Haurum 2000 Poor correspondence between predicted and experimental binding of peptides to class I MHC molecules Tissue Antigens 55 519 531 1:CAS:528:DC%2BD3cXlvVyrsr4%3D 10.1034/j.1399-0039.2000.550603.x 10902608
21. MH Andersen JE Bonfill A Neisig G Arsequell I Sondergaard G Valencia J Neefjes J Zeuthen T Elliott JS Haurum 1999 Phosphorylated peptides can be transported by TAP molecules, presented by class I MHC molecules, and recognized by phosphopeptide-specific CTL J Immunol 163 3812 3818 1:CAS:528: DyaK1MXmt1yjurk%3D 10490979
22. T Krejsgaard CS Vetter-Kauczok A Woetmann P Lovato T Labuda KW Eriksen Q Zhang JC Becker N Odum 2006 Jak3- and JNK-dependent vascular endothelial growth factor expression in cutaneous T-cell lymphoma Leukemia 20 1759 1766 1:CAS:528:DC%2BD28XhtVOlsbnL 10.1038/sj.leu.2404350 16932349
23. MH Andersen IM Svane P Kvistborg OJ Nielsen E Balslev S Reker JC Becker P thor Straten 2005 Immunogenicity of Bcl-2 in patients with cancer Blood 105 728 734 1:CAS:528:DC%2BD2MXltlGnsQ%3D%3D 10.1182/blood-2004-07-2548 15367432
24. M McCutcheon N Wehner A Wensky M Kushner S Doan L Hsiao P Calabresi T Ha TV Tran KM Tate J Winkelhake EG Spack 1997 A sensitive ELISPOT assay to detect low-frequency human T lymphocytes J Immunol Methods 210 149 166 1:CAS:528:DyaK1cXht1Wntbc%3D 10.1016/S0022-1759(97)00182-8 9520298
25. R Trepiakas A Berntsen SR Hadrup J Bjorn PF Geertsen P thor Straten MH Andersen AE Pedersen A Soleimani T Lorentzen JS Johansen IM Svane 2010 Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial Cytotherapy 12 6 721 734 1:CAS:528:DC%2BC3cXht1Snsb%2FF 10.3109/14653241003774045 20429791
26. A Berntsen R Trepiakas L Wenandy PF Geertsen P thor Straten MH Andersen AE Pedersen MH Claesson T Lorentzen JS Johansen IM Svane 2008 Therapeutic dendritic cell vaccination of patients with metastatic renal cell carcinoma: a clinical phase 1/2 trial J Immunother 31 771 780 1:CAS:528:DC%2BD1cXhtFCrtLzL 10.1097/CJI.0b013e3181833818 18779742
27. IM Svane AE Pedersen JS Johansen HE Johnsen D Nielsen C Kamby S Ottesen E Balslev E Gaarsdal K Nikolajsen MH Claesson 2007 Vaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer; monitoring of serum YKL-40 and IL-6 as response biomarkers Cancer Immunol Immunother 56 1485 1499 1:CAS:528:DC%2BD2sXntVOlsb4%3D 10.1007/s00262-007-0293-4 17285289
28. H Suzuki DF Graziano J McKolanis OJ Finn 2005 T cell-dependent antibody responses against aberrantly expressed cyclin B1 protein in patients with cancer and premalignant disease Clin Cancer Res 11 1521 1526 1:CAS:528: DC%2BD2MXhvVSrsbY%3D 10.1158/1078-0432.CCR-04-0538 15746055
29. LA Vella M Yu SR Fuhrmann M El-Amine DE Epperson OJ Finn 2009 Healthy individuals have T-cell and antibody responses to the tumor antigen cyclin B1 that when elicited in mice protect from cancer Proc Natl Acad Sci USA 106 14010 14015 1:CAS:528:DC%2BD1MXhtFWksL7E 10.1073/pnas.0903225106 19666607
30. GA Rizzuto T Merghoub D Hirschhorn-Cymerman C Liu AM Lesokhin D Sahawneh H Zhong KS Panageas MA Perales G tan-Bonnet JD Wolchok AN Houghton 2009 Self-antigen-specific CD8 + T cell precursor frequency determines the quality of the antitumor immune response J Exp Med 206 849 866 1:CAS:528: DC%2BD1MXkvVSiu7w%3D 10.1084/jem.20081382 19332877